Core Viewpoint - The stock of药捷安康 (02617) experienced a significant surge of over 200% recently but faced a sharp decline of 18% in early trading, with a current price of 167.5 HKD and a market capitalization dropping below 70 billion HKD [1] Group 1: Stock Performance - The stock saw a cumulative increase of over 200% before the recent decline [1] - As of the latest report, the stock price fell by 12.99% with a trading volume of 333 million HKD [1] Group 2: Company Developments - The company has been included in the Hong Kong Stock Connect list effective from September 8 [1] -药捷安康 focuses on discovering and developing small molecule innovative therapies for oncology, inflammation, and cardiovascular metabolic diseases [1] - As of June 30, 2025, the company has six clinical-stage candidates and several preclinical candidates in its pipeline [1] Group 3: Financial Performance - The company reported no revenue from its main business in the first half of the year, with other income declining from 10.4 million HKD to 3.6 million HKD, a decrease of 65.1% [1] - The decline in other income was attributed to a reduction in bank deposit interest and investment income by 4.1 million HKD and a decrease in government subsidies by 2.7 million HKD [1] - Research and development costs decreased by 30.9% to 98.4 million HKD [1] - The company recorded a pre-tax loss of 123 million HKD, an improvement compared to a loss of 160 million HKD in the same period of 2024 [1]
药捷安康早盘重挫18% 总市值不足700亿港元 上半年集团未取得主营业务收入